45% fat, 35% carbohydrates) for 21 days, followed by a single low intraperitoneal dose of streptozotocin (STZ, 10 mg/kg body weight) in 0.1 M sodium citrate buffer (pH 4.5) 33
Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes
Cost-benefit assessment is personal
Moreover, the highly coordinated activation of lipid oxidative pathways, restoration of mitochondrial and peroxisomal gene networks, selective induction of pro-resolving lipid mediators (such as ()15-HETE), and concurrent suppression of inflammatory and fibrotic signaling pathways indicate an active and structured reprogramming of adipose tissue metabolism that is unlikely to arise from weight reduction alone
Anal Biochem 72:248254
Is microdosing safe and FDA-approved